Evidence map›Paper›PMID 30214196›Full record

ArticleInternational journal of nanomedicine2018

Macropinocytosis activated by oncogenic Dbl enables specific targeted delivery of Tat/pDNA nano-complexes into ovarian cancer cells.

Xiuran Niu, Zhihui Gao, Shanshan Qi, Linjia Su, Nan Yang, Xiuli Luan, Jia Li, Qing Zhang, Yingli An, Sihe Zhang

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Lysophosphatidic acid-induced Arf6-driven macropinocytosis of CD147International journal of biological sciences · 2026
    Article
  3. Article
  4. Nucleic acid vaccination strategies for ovarian cancer.Frontiers in bioengineering and biotechnology · 2022
    Review
  5. Article
  6. Review
  7. Macropinocytosis: mechanism and targeted therapy in cancers.American journal of cancer research · 2021
    Review
  8. Article
  9. Article
  10. Arf6-driven endocytic recycling of CD147 determines HCC malignant phenotypes.Journal of experimental & clinical cancer research : CR · 2019
    Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Xiuran NiuDepartment of Cell Biology, School of Medicine, Nankai University, Tianjin, People's Republic of China, sihezhang@nankai.edu.cn.
Zhihui GaoDepartment of Cell Biology, School of Medicine, Nankai University, Tianjin, People's Republic of China, sihezhang@nankai.edu.cn.
Shanshan QiDepartment of Cell Biology, School of Medicine, Nankai University, Tianjin, People's Republic of China, sihezhang@nankai.edu.cn.
Linjia SuDepartment of Cell Biology, School of Medicine, Nankai University, Tianjin, People's Republic of China, sihezhang@nankai.edu.cn.
Nan YangDepartment of Cell Biology, School of Medicine, Nankai University, Tianjin, People's Republic of China, sihezhang@nankai.edu.cn.
Xiuli LuanDepartment of Cell Biology, School of Medicine, Nankai University, Tianjin, People's Republic of China, sihezhang@nankai.edu.cn.
Jia LiDepartment of Cell Biology, School of Medicine, Nankai University, Tianjin, People's Republic of China, sihezhang@nankai.edu.cn.
Qing ZhangDepartment of Clinical Laboratory, Cancer Hospital of Tianjin Medical University, Tianjin, People's Republic of China.
Yingli AnState Key Laboratory of Medicinal Chemical Biology and Institute of Polymer Chemistry, Nankai University, Tianjin, People's Republic of China.
Sihe ZhangDepartment of Cell Biology, School of Medicine, Nankai University, Tianjin, People's Republic of China, sihezhang@nankai.edu.cn.
Nankai University · CNTianjin Medical University Cancer Institute and Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSuccessful implementation of gene therapy heavily relies on efficiently delivering genetic materials and specific targeting into cells. Oncogene-driven endocytosis stimulates nutrient uptake and also develops an endocytosis-mediated defense against therapeutic agents. Cell-penetrating peptides, typically HIV-Tat, are well known for efficient delivery of nucleic acid drugs but lack targeting specificity. Various passive targeting strategies were pursued to enhance the tumor targeting efficiency; however, they are still limited by complicated cellular endocytosis routes and the heterogeneity of cancer types.

methodsTat/pDNA complexes were noncovalently compacted and their physiochemical properties were determined. The siRNA pool and pLV-RNAi-GFP lentivirus were used to knock down

resultspGL3 plasmid DNA was noncovalently compacted with the Tat peptide into nano-size complexes at high N/P ratios. Macropinocytosis, a clathrin- and caveolin-independent endocytosis process, was shown to contribute to the uptake of middle-sized (∼600 nm) Tat/pGL3 complexes. Cell-type-specific variation in macropinocytosis was essentially controlled by the action of the

conclusionSuch an aspect can be exploited to selectively confer targeted delivery of Tat/pDNA nano-complexes into ovarian cancer cells. Our work provides a novel alternative for targeted delivery of cell-penetrating peptide-based nucleic acid drugs into certain tumor types if specific endocytosis pathways are used.

Indexed as

Drug Delivery SystemsPinocytosisDNAFemaleGuanine Nucleotide Exchange FactorsHumansNanocompositesOvarian NeoplasmsPlasmidsProtein BindingProto-Oncogene ProteinsSignal Transductiontat Gene Products, Human Immunodeficiency VirusTumor Cells, CulturedDNAGuanine Nucleotide Exchange FactorsMCF2 protein, humanProto-Oncogene Proteinstat Gene Products, Human Immunodeficiency Virusmacropinocytosisonco-DblRac1targeting deliveryTat/pDNA complex

Identifiers

PMID30214196
PMCPMC6122892
OpenAlexW2889494863

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.